Education
About Us
Working with TipRanks
Follow Us
Korro Bio (KRRO)
NASDAQ:KRRO
KRRO Stock Chart & Stats
$12.57
-$1.03(-2.68%)
At close: 4:00 PM EST
$12.57
-$1.03(-2.68%)
Day’s Range― - ―
52-Week Range$5.20 - $55.89
Previous CloseN/A
Volume28.02K
Average Volume (3M)734.66K
Market Cap
$118.38M
Enterprise Value$137.89M
Total Cash (Recent Filing)$93.48M
Total Debt (Recent Filing)$44.67M
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Mar 31, 2026EPS Estimate
-2.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding9,417,295
10 Day Avg. Volume1,808,258
30 Day Avg. Volume734,659
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.12
Price to Sales (P/S)149.54
P/FCF Ratio-4.36
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue18.71
Enterprise Value/Gross Profit18.71
Enterprise Value/Ebitda-1.56
Forecast
1Y Price Target
$18.00Price Target Upside43.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst Conviction And Market PotentialAnalyst upgrades to Buy and Overweight reflect conviction that KRRO-121's mechanism to stabilize glutamine synthase could address a sizeable urea cycle disorder and hepatic encephalopathy market and help rebuild investor confidence.
Delivery Platform AdvancementSwitching to GalNAc-conjugated delivery for KRRO-121 enhances targeted liver uptake versus prior lipid nanoparticle approaches, increasing the likelihood of successful translation to human studies.
Preclinical Efficacy And SafetyPreclinical studies showed KRRO-121 reduced ammonia in multiple animal models and demonstrated liver-selective distribution with minimal off-target exposure, supporting a favorable safety and proof-of-concept profile.
Bears Say
Clinical And Regulatory Execution RiskKey execution risks persist around first-in-human trial design, durability of dosing in humans, and the potential for regulators to demand demonstration of reduced clinical events rather than only ammonia lowering.
Financial And Investor Confidence RiskFailure of the earlier KRRO-110 program triggered a significant share selloff and weakened investor trust, while limited cash runway increases the likelihood of future financing and potential dilution.
Operational And Collaboration DisruptionA substantial workforce reduction, a paused collaboration with Novo, and the chief medical officer's resignation signal operational disruption that could delay development timelines and heighten execution risk.
Korro Bio News
KRRO FAQ
What was Korro Bio’s price range in the past 12 months?
Korro Bio lowest stock price was $5.20 and its highest was $55.89 in the past 12 months.
What is Korro Bio’s market cap?
Korro Bio’s market cap is $118.38M.
When is Korro Bio’s upcoming earnings report date?
Korro Bio’s upcoming earnings report date is Mar 31, 2026 which is in 50 days.
How were Korro Bio’s earnings last quarter?
Korro Bio released its earnings results on Nov 12, 2025. The company reported -$1.92 earnings per share for the quarter, beating the consensus estimate of -$2.594 by $0.674.
Is Korro Bio overvalued?
According to Wall Street analysts Korro Bio’s price is currently Undervalued.
Does Korro Bio pay dividends?
Korro Bio does not currently pay dividends.
What is Korro Bio’s EPS estimate?
Korro Bio’s EPS estimate is -2.07.
How many shares outstanding does Korro Bio have?
Korro Bio has 9,417,295 shares outstanding.
What happened to Korro Bio’s price movement after its last earnings report?
Korro Bio reported an EPS of -$1.92 in its last earnings report, beating expectations of -$2.594. Following the earnings report the stock price went down -79.313%.
Which hedge fund is a major shareholder of Korro Bio?
Currently, no hedge funds are holding shares in KRRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Korro Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (43.20% Upside)
$18.00 (43.20% Upside)
Hedge Fund Trend
Increased
By 91.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-88.72%
12-Months-Change
Fundamentals
Return on Equity
-63.46%
Trailing 12-Months
Asset Growth
-33.67%
Trailing 12-Months
Company Description
Korro Bio
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
KRRO Stock 12 Month Forecast
Average Price Target
$18.00
▲(43.20% Upside)
Technical Analysis
Assembly Biosciences
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Aura Biosciences Inc
―